Combinatorial anti-angiogenic gene therapy in a human malignant mesothelioma model

Kubo,Shuji; Takagi-Kimura,Misato; Kasahara,Noriyuki

doi:10.3892/or.2015.4058

Combinatorial anti-angiogenic gene therapy in a human malignant mesothelioma model

Authors:
- Shuji Kubo
- Misato Takagi-Kimura
- Noriyuki Kasahara
View Affiliations

Affiliations: Department of Genetics, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan, Departments of Cell Biology and Pathology, University of Miami, Miami, FL, USA
Published online on: June 12, 2015 https://doi.org/10.3892/or.2015.4058
Pages: 633-638

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Anti-angiogenic gene therapy represents a promising strategy for cancer; however, it has rarely been tested in malignant mesothelioma, a highly aggressive tumor associated with asbestos with poor prognosis. In the present study, we investigated whether anti-angiogenic factors such as angiostatin, endostatin and the soluble form of vascular endothelial growth factor receptor 2 (sFlk1) were able to inhibit endothelial cell proliferation via lentivirus-mediated gene transfer into malignant mesothelioma cells in culture. We also assessed whether a dual-agent strategy had greater therapeutic benefit. Human malignant pleural mesothelioma MSTO-211H cells were transduced using lentiviral vectors that individually expressed angiostatin, endostatin and sFlk1 and linked to enhanced green fluorescent protein (EGFP) marker gene expression via an internal ribosome entry site. The lentivirus expressing EGFP alone was used as a control. The resultant cells designated as MSTO-A, MSTO-E, MSTO-F and MSTO-C were confirmed by western blot analysis and fluorescence microscopy to stably express the corresponding proteins. No differences were observed in the in vitro growth rates between any of these cells. However, co-culture of MSTO-A, MSTO-E and MSTO-F showed significant suppression of human umbilical endothelial cell growth in vitro compared with that of MSTO-C. Furthermore, a combination of any two among MSTO-A, MSTO-E and MSTO-F significantly enhanced efficacy. These results suggest that combinatorial anti-angiogenic gene therapy targeting different pathways of endothelial growth factor signaling has the potential for greater therapeutic efficacy than that of a single-agent regimen.

View Figures

View References

1	Ismail-Khan R, Robinson LA, Williams CC Jr, Garrett CR, Bepler G and Simon GR: Malignant pleural mesothelioma: A comprehensive review. Cancer Control. 13:255–263. 2006.PubMed/NCBI
2	Tsao AS, Wistuba I, Roth JA and Kindler HL: Malignant pleural mesothelioma. J Clin Oncol. 27:2081–2090. 2009. View Article : Google Scholar : PubMed/NCBI
3	van der Most RG, Robinson BW and Nelson DJ: Gene therapy for malignant mesothelioma: Beyond the infant years. Cancer Gene Ther. 13:897–904. 2006. View Article : Google Scholar : PubMed/NCBI
4	Kotova S, Wong RM and Cameron RB: New and emerging therapeutic options for malignant pleural mesothelioma: Review of early clinical trials. Cancer Manag Res. 7:51–63. 2015.PubMed/NCBI
5	Weis SM and Cheresh DA: Tumor angiogenesis: Molecular pathways and therapeutic targets. Nat Med. 17:1359–1370. 2011. View Article : Google Scholar : PubMed/NCBI
6	Redlitz A, Daum G and Sage EH: Angiostatin diminishes activation of the mitogen-activated protein kinases ERK-1 and ERK-2 in human dermal microvascular endothelial cells. J Vasc Res. 36:28–34. 1999. View Article : Google Scholar : PubMed/NCBI
7	O’reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH and Folkman J: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 79:315–328. 1994. View Article : Google Scholar
8	Shichinohe T, Bochner BH, Mizutani K, Nishida M, Hegerich-Gilliam S, Naldini L and Kasahara N: Development of lentiviral vectors for antiangiogenic gene delivery. Cancer Gene Ther. 8:879–889. 2001. View Article : Google Scholar
9	O’reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR and Folkman J: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:277–285. 1997. View Article : Google Scholar
10	Kuo CJ, Farnebo F, Yu EY, Christofferson R, Swearingen RA, Carter R, von Recum HA, Yuan J, Kamihara J, Flynn E, et al: Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci USA. 98:4605–4610. 2001. View Article : Google Scholar : PubMed/NCBI
11	Szentirmai O, Baker CH, Bullain SS, Lin N, Takahashi M, Folkman J, Mulligan RC and Carter BS: Successful inhibition of intracranial human glioblastoma multiforme xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2: Laboratory investigation. J Neurosurg. 108:979–988. 2008. View Article : Google Scholar : PubMed/NCBI
12	Wu Y, Li ZY, Zhao X, Kan B and Wei YQ: Inhibition of ovarian tumor growth by gene therapy with recombinant soluble vascular endothelial growth factor receptor 2. Hum Gene Ther. 17:941–948. 2006. View Article : Google Scholar : PubMed/NCBI
13	Zucali PA, Ceresoli GL, De Vincenzo F, Simonelli M, Lorenzi E, Gianoncelli L and Santoro A: Advances in the biology of malignant pleural mesothelioma. Cancer Treat Rev. 37:543–558. 2011. View Article : Google Scholar : PubMed/NCBI
14	Remon J, Lianes P, Martínez S, Velasco M, Querol R and Zanui M: Malignant mesothelioma: New insights into a rare disease. Cancer Treat Rev. 39:584–591. 2013. View Article : Google Scholar : PubMed/NCBI
15	Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G, Puntoni R, Mutti L and Procopio A: Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol. 193:468–475. 2001. View Article : Google Scholar : PubMed/NCBI
16	Kumar-Singh S, Weyler J, Martin MJ, Vermeulen PB and Van Marck E: Angiogenic cytokines in mesothelioma: A study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathol. 189:72–78. 1999. View Article : Google Scholar : PubMed/NCBI
17	Yasumitsu A, Tabata C, Tabata R, Hirayama N, Murakami A, Yamada S, Terada T, Iida S, Tamura K, Fukuoka K, et al: Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J Thorac Oncol. 5:479–483. 2010. View Article : Google Scholar : PubMed/NCBI
18	Kourlas H and Abrams P: Ranibizumab for the treatment of neovascular age-related macular degeneration: A review. Clin Ther. 29:1850–1861. 2007. View Article : Google Scholar : PubMed/NCBI
19	Jenab-Wolcott J and Giantonio BJ: Bevacizumab: Current indications and future development for management of solid tumors. Expert Opin Biol Ther. 9:507–517. 2009. View Article : Google Scholar : PubMed/NCBI
20	Langer C and Soria JC: The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer. Clin Lung Cancer. 11:82–90. 2010. View Article : Google Scholar : PubMed/NCBI
21	Ceresoli GL, Zucali PA, Mencoboni M, Botta M, Grossi F, Cortinovis D, Zilembo N, Ripa C, Tiseo M, Favaretto AG, et al: Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. Br J Cancer. 109:552–558. 2013. View Article : Google Scholar : PubMed/NCBI
22	Dowell JE, Dunphy FR, Taub RN, Gerber DE, Ngov L, Yan J, Xie Y and Kindler HL: A multicenter phase ii study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer. 77:567–571. 2012. View Article : Google Scholar : PubMed/NCBI
23	Kubo S and Mitani K: A new hybrid system capable of efficient lentiviral vector production and stable gene transfer mediated by a single helper-dependent adenoviral vector. J Virol. 77:2964–2971. 2003. View Article : Google Scholar : PubMed/NCBI
24	Kubo S, Seleme MC, Soifer HS, Perez JL, Moran JV, Kazazian HH Jr and Kasahara N: L1 retrotransposition in non-dividing and primary human somatic cells. Proc Natl Acad Sci USA. 103:8036–8041. 2006. View Article : Google Scholar
25	Takahashi S: Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull. 34:1785–1788. 2011. View Article : Google Scholar : PubMed/NCBI
26	Bougatef F, Quemener C, Kellouche S, Naïmi B, Podgorniak MP, Millot G, Gabison EE, Calvo F, Dosquet C, Lebbé C, et al: EMMPRIN promotes angiogenesis through hypoxia-inducible factor-2alpha-mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2. Blood. 114:5547–5556. 2009. View Article : Google Scholar : PubMed/NCBI
27	Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, Ferrara N, Nagy A, Roos KP and Iruela-Arispe ML: Autocrine VEGF signaling is required for vascular homeostasis. Cell. 130:691–703. 2007. View Article : Google Scholar : PubMed/NCBI
28	Robinson CJ and Stringer SE: The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci. 114:853–865. 2001.PubMed/NCBI
29	Li Q, Yano S, Ogino H, Wang W, Uehara H, Nishioka Y and Sone S: The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Clin Cancer Res. 13:5918–5925. 2007. View Article : Google Scholar : PubMed/NCBI
30	Kawasaki Y, Tamamoto A, Takagi-Kimura M, Maeyama Y, Yamaoka N, Terada N, Okamura H, Kasahara N and Kubo S: Replication-competent retrovirus vector-mediated prodrug activator gene therapy in experimental models of human malignant mesothelioma. Cancer Gene Ther. 18:571–578. 2011. View Article : Google Scholar : PubMed/NCBI
31	Kubo S, Takagi-Kimura M, Logg CR and Kasahara N: Highly efficient tumor transduction and antitumor efficacy in experimental human malignant mesothelioma using replicating gibbon ape leukemia virus. Cancer Gene Ther. 20:671–677. 2013. View Article : Google Scholar : PubMed/NCBI
32	Kubo S, Kawasaki Y, Yamaoka N, Tagawa M, Kasahara N, Terada N and Okamura H: Complete regression of human malignant mesothelioma xenografts following local injection of midkine promoter-driven oncolytic adenovirus. J Gene Med. 12:681–692. 2010.PubMed/NCBI
33	Takagi-Kimura M, Yamano T, Tagawa M and Kubo S: Oncolytic virotherapy for osteosarcoma using midkine promoter-regulated adenoviruses. Cancer Gene Ther. 21:126–132. 2014. View Article : Google Scholar : PubMed/NCBI
34	Takagi-Kimura M, Yamano T, Tamamoto A, Okamura N, Okamura H, Hashimoto-Tamaoki T, Tagawa M, Kasahara N and Kubo S: Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma. Cancer Sci. 104:1433–1439. 2013. View Article : Google Scholar : PubMed/NCBI